Gilead Sciences

This study tested a drug called seladelpar in 96 adults with primary biliary cholangitis (PBC), a rare liver disease. Participants had not responded well or could not tolerate the standard treatment. The goal was to see if seladelpar could lower a key liver enzyme (alkaline phosp…

This study tested a new drug called sacituzumab govitecan against standard treatments in 711 people with advanced bladder cancer that had spread or couldn't be removed. The goal was to see if the new drug helped people live longer. Participants received either the new drug or a t…

This early-stage study tested a new experimental HIV medicine, GS-3242, in 27 people living with HIV-1. The goal was to see if the drug is safe and can lower the amount of virus in the blood over 11 days. Participants had not taken HIV medication for at least 12 weeks before the …

This study looked at 33 adults with well-controlled HIV who switched from a monthly injectable treatment (CAB+RPV) to a daily oral pill (B/F/TAF). The main goal was to check if the switch was safe, especially for those who couldn't or didn't want to continue injections. Over 12 w…

This early-stage trial tested two experimental therapeutic vaccines, GS-2829 and GS-6779, in 83 healthy people and those with chronic hepatitis B. The main goal was to check safety and tolerability, while also measuring immune responses. The vaccines are designed to help the body…

This study tested a combination of two lab-made antibodies (VRC07-523LS and CAP256V2LS) and an immune-boosting pill (vesatolimod) in 20 women with HIV who were already on standard antiretroviral therapy. The goal was to see if the regimen is safe and might help control the virus …

This study tested the HIV medication Genvoya (a single daily pill) in 129 teenagers and children with HIV. The goal was to check how the drug is processed in the body, confirm the right dose, and see if it is safe. Participants included teens new to HIV treatment and children who…

This phase 2 trial tested whether semaglutide (a diabetes drug) combined with cilofexor and firsocostat (two experimental liver drugs) can improve liver scarring and resolve NASH in people with cirrhosis. 457 participants with compensated cirrhosis due to NASH were randomly assig…

This study looked at the long-term safety of the drug sacituzumab govitecan (Trodelvy) in 25 people with metastatic solid tumors who were already benefiting from the treatment. Participants continued to receive the drug intravenously, and researchers tracked any side effects or l…

This early-stage study looked at how the drug bulevirtide behaves in people with chronic hepatitis D who also have normal or impaired kidney function. Researchers measured drug levels in the blood, its effect on bile acids, and overall safety. The study enrolled 41 adults and gav…

This completed Phase 1 study looked at how the drug seladelpar (Livdelzi) is processed in 24 people with primary biliary cholangitis (PBC) who also have liver impairment. Researchers measured drug levels in the blood and urine to see how the liver condition affects the drug. The …

This completed Phase 1 study looked at how the drug bulevirtide (Hepcludex) behaves in the body of people with normal liver function and those with liver impairment. Researchers measured drug levels in the blood and how quickly it is cleared. The study involved 74 participants an…